Date: 2014-07-09
Type of information: Grant
Company: Domainex (UK)
Investors: Biomedical Catalyst Fund (UK)
Amount: £1.4 million (€1.76 million)
Funding type: grant
Planned used: * The funds will be used to support further development of Domainex\'s small-molecule inhibitors of two closely-related pro-inflammatory kinases - TBK1 and IKK-epsilon (IKKε) towards Phase I clinical studies. Its lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease (COPD) than either roflumulast or a p38 inhibitor. Domainex has previously shown that its inhibitors of TBK1 and IKKε are potent anti-inflammatory agents, which can inhibit signaling pathways activated by Toll-like Receptors and IL-17. This data suggests that these compounds may have utility in COPD and other inflammatory diseases including rheumatoid arthritis, lupus and psoriasis.
Others: * On July 9, 2014, Domainex Ltd, a UK-based drug discovery company developing first-in-class small-molecule inhibitors of two closely-related pro-inflammatory kinases - TBK1 and IKK-epsilon (IKKε), announced that its has been awarded £1.4m by the Technology Strategy Board via the Biomedical Catalyst. This integrated translational funding programme is used to support innovative ideas that could provide significant positive healthcare and economic impact. It is intended to help bridge the ‘valley of death\' that exists between when a bright new idea is developed in the laboratory and the point when a new drug or technology can be invested in by the market.
Therapeutic area: Inflammatory diseases - Respiratory diseases
